Natural History Without Dutasteride Treatment
Without dutasteride treatment, your patient with an 82 mL prostate faces a significantly increased risk of disease progression, including acute urinary retention (AUR) and eventual need for BPH-related surgery, with the absolute benefit of treatment being directly proportional to his large prostate volume.
Understanding the Progressive Nature of BPH
Your patient's prostate volume of 82 mL places him at high risk for clinical progression. The evidence clearly demonstrates that men with larger prostates and those on watchful waiting face an "increasingly worse prognosis" over time 1. This is not a static condition—BPH is progressive, particularly in men with prostatic enlargement of this magnitude.
Specific Risks Without Treatment
Based on the REDUCE study data examining asymptomatic or mildly symptomatic men with enlarged prostates:
- 36% experienced clinical progression over 4 years in the placebo group (defined as ≥4 point worsening in symptom scores, AUR, urinary tract infection, or BPH-related surgery) 2
- The absolute risk reduction with dutasteride was 15%, meaning without treatment, he faces this additional burden
- For AUR specifically, the absolute risk increase without treatment was 6.0% 2
- For BPH-related surgery, the absolute risk increase was 3.8% 2
The Volume-Risk Relationship
The critical point: "the absolute benefit increasing with rising prostate volume" 1. At 82 mL, your patient is well above the threshold where 5-ARI therapy demonstrates maximal benefit. The guidelines specify that dutasteride reduces AUR risk by:
- 67% with finasteride monotherapy
- 79% with combination therapy 1
What Happens Over Time
Symptom Progression
Without treatment, conservatively managed patients experience:
- Progressive worsening of LUTS over time
- The natural history shows continued prostate growth
- Symptom deterioration that may eventually necessitate intervention anyway 1
Long-term Complications
The evidence demonstrates that dutasteride "reduces the risk (rather than delay)" of serious complications 3. This means without treatment, he's not just postponing problems—he's accepting a higher absolute risk of:
- Acute urinary retention episodes
- Emergency catheterization
- Eventual surgical intervention under potentially less favorable circumstances
The Treatment Alternative He's Declining
For context on what he's forgoing:
Dutasteride would provide:
- 26-30% reduction in prostate volume over 4 years 4
- 41% relative risk reduction in clinical progression 2
- Number needed to treat of only 7 to prevent one case of clinical progression 2
- Maintained benefit over years (4-6 year data show sustained improvements) 1
Common Pitfalls in This Discussion
Don't minimize the progression risk. At 82 mL, this is not a "wait and see" situation—the prostate volume itself predicts worse outcomes. The AUA guidelines specifically state that patients can be offered 5-ARI "to prevent progression of the disease" even without significant bother, though the decision requires informed consent about risks versus benefits 1.
Address his concerns directly. Sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) occur but are "reversible and uncommon after the first year of therapy" 1. The absolute rates are 1-8% 5. However, post-finasteride syndrome concerns exist, though the data supporting this remains controversial 6.
The Bottom Line for Your Patient
He needs to understand that doing nothing is an active choice with measurable consequences. Over 4 years, roughly 1 in 3 men with his prostate size will experience clinical progression without treatment. The risks of AUR and surgery are real and increase with his prostate volume. While dutasteride has side effects, the alternative is accepting a substantially higher risk of urological complications that will likely require more invasive interventions later.
If he remains reluctant about daily dutasteride, consider discussing:
- Alpha-blocker monotherapy for symptom relief (though this doesn't prevent progression) 1
- Combination therapy if immediate symptom relief is needed 1
- Close monitoring with clear thresholds for reconsidering treatment
The evidence strongly favors treatment at his prostate volume, but the final decision requires weighing his quality of life priorities against objective progression risks.